Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spirulina peptidoglycan complex (SPGC) is a purified biological extract derived from the cell walls of the cyanobacterium *Arthrospira platensis* (Spirulina). Developed by Beijing Huashi Tianfu Biopharmaceutical Technology, SPGC is being investigated as an antineoplastic agent for the treatment of gastric cancer and gastric adenocarcinoma. The complex is thought to function as an immunomodulator, potentially activating Toll-like receptors (notably TLR2) on immune cells to stimulate a pro-inflammatory, anti-tumor response. Additionally, it has been shown to induce apoptosis in gastric cancer cells and inhibit tumor angiogenesis. Clinical development in China has progressed to Phase 2 trials for advanced gastric malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spirulina peptidoglycan complex.